B. Riley initiated coverage of Zymeworks (ZYME) with a Buy rating and $30 price target The firm views Zymeworks as a multifunctional therapeutics biotech with “highly differentiated” and “clinically de-risked” therapies. It expects Ziihhera to expand into gastric and breast cancer. The upcoming Jazz Pharmaceuticals (JAZZ) Phase 3 HERIZON-GEA readout to present potential upside to the Street’s estimates, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZYME:
- Zymeworks Appoints New Acting Chief Development Officer to Boost Therapeutic Advancements
- Zymeworks appoints Adam Schayowitz as Acting Chief Development Officer
- Zymeworks’ Zanidatamab Shows Promising Potential in HERIZON-GEA-01 Trial with Significant Stock Upside
- Strategic Shift to Zanidatamab Drives Optimistic Buy Rating for Zymeworks
- Strategic Focus and Promising Pipeline Drive Buy Rating for Zymeworks